Mycenax Biotech Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	649.64	683.92	652.62	732.28	774.27	665.34
Revenue Growth (YoY)	-3.45%	4.80%	-10.88%	-5.42%	16.37%	70.23%
Cost of Revenue	871.33	925.28	1,028	845.95	636.66	478.81
Gross Profit	-221.69	-241.36	-375.19	-113.67	137.61	186.53
Selling, General & Admin	143.77	141.94	152.23	156.16	133.96	93.77
Research & Development	78.69	78.19	75.81	144	96.13	46.5
Operating Expenses	221.64	220.18	226.91	331.32	222.94	151.13
Operating Income	-443.32	-461.54	-602.1	-445	-85.33	35.4
Interest Expense	-28.1	-26.16	-23.46	-15.42	-1.17	-0.87
Interest & Investment Income	5.08	8.53	17.66	3.8	0.31	1.48
Earnings From Equity Investments	-17.37	-12.94	-8.7	-0.76	-	-
Currency Exchange Gain (Loss)	-12.68	14.58	3.35	13.29	-1.35	-9.22
Other Non Operating Income (Expenses)	-5.81	-4.96	0.75	0.21	-0.11	0.9
EBT Excluding Unusual Items	-502.2	-482.5	-612.5	-443.87	-87.65	27.7
Gain (Loss) on Sale of Assets	0.22	-	-	-20.11	0.13	0.27
Other Unusual Items	1.07	1.07	-71.48	1.13	-	-
Pretax Income	-489.07	-469.59	-683.98	-462.84	-87.52	27.97
Income Tax Expense	-9.6	-2.46	-1.13	-9.21	2.34	-2.98
Net Income	-479.46	-467.13	-682.85	-453.63	-89.86	30.95
Net Income to Common	-479.46	-467.13	-682.85	-453.63	-89.86	30.95
Shares Outstanding (Basic)	207	206	206	165	148	128
Shares Outstanding (Diluted)	207	206	206	165	148	129
Shares Change (YoY)	0.52%	0.23%	24.31%	11.35%	15.36%	2.37%
EPS (Basic)	-2.32	-2.27	-3.32	-2.74	-0.61	0.24
EPS (Diluted)	-2.32	-2.27	-3.32	-2.74	-0.61	0.24
Free Cash Flow	-293.24	-522.11	-426.81	-777.12	-1,244	-86.04
Free Cash Flow Per Share	-1.42	-2.54	-2.08	-4.70	-8.38	-0.67
Gross Margin	-34.12%	-35.29%	-57.49%	-15.52%	17.77%	28.04%
Operating Margin	-68.24%	-67.48%	-92.26%	-60.77%	-11.02%	5.32%
Profit Margin	-73.80%	-68.30%	-104.63%	-61.95%	-11.61%	4.65%
Free Cash Flow Margin	-45.14%	-76.34%	-65.40%	-106.12%	-160.71%	-12.93%
EBITDA	-203.95	-206.91	-338.27	-219.7	44.33	150.83
EBITDA Margin	-31.39%	-30.25%	-51.83%	-30.00%	5.73%	22.67%
D&A For EBITDA	239.37	254.63	263.83	225.3	129.66	115.43
EBIT	-443.32	-461.54	-602.1	-445	-85.33	35.4
EBIT Margin	-68.24%	-67.48%	-92.26%	-60.77%	-11.02%	5.32%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.